Aptar CSP Technologies, a company involved in active material science solutions, entered into a strategic collaboration with Porton Pharmatech Co., Ltd, a subsidiary of Porton Pharma Solutions Co., Ltd, a global CDMO, to bring Activ-Blister Solutions to the Asia-Pacific (APAC) region. The move follows successful commercialization and approval of Activ-Blister technology with two HIV medications currently marketed in North America and the EMEA region.

The collaboration with Porton provides pharma developers in the APAC region with access to a local development and manufacturing resource for leveraging Aptar CSP’s Activ-Blister solutions to protect their sensitive drugs. Bringing production of this technology closer to patients and consumers will help mitigate supply chain disruptions and expedite time to market.

Activ-Blister Solutions integrates Aptar CSP’s 3-Phase Activ-Polymer platform technology into individual blister cavities or in a fishbone blister format to provide microclimate protection for sensitive drug products. The technology can be customized specifically for the drug developer’s formulation to provide a broad spectrum of specific drug protection including moisture adsorption, and oxygen and odor scavenging. The technology can also scavenge volatile organic compounds (VOCs) and emit aromas. Most recently, Aptar CSP leveraged the Activ-Blister platform to develop a solution to mitigate risk of mutagenic N-nitrosamine impurity formation and drug degradation.

Aptar CSP brought local production of Activ-Vial technology to diabetes patients in the China region early this year. cGMP produced Activ-Vial products are now available on site in Guangzhou for commercial launch. 

“Expanding global manufacturing sites for Activ-Blister technology reflects our commitment to delivering global access to innovative active material science solutions for patients and consumers,” said Badre Hammond, vice president commercial operations and general manager APAC, Aptar CSP Technologies. “This collaboration with Porton enables us to better serve the regional market for both local production and export business.”

“Porton is proud to collaborate with Aptar CSP Technologies to bring the first application of Activ-Blister technology to the APAC market,” said Donna Deng, director of strategic procurement at Porton Pharmatech. “This partnership highlights Porton’s global strategic vision and mission of bringing quality medicine to the public.”